RT Journal Article
T1 Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
A1 Conteduca, Vincenza
A1 Jayaram, Anuradha
A1 Romero-Laorden, Nuria
A1 Wetterskog, Daniel
A1 Salvi, Samanta
A1 Gurioli, Giorgia
A1 Scarpi, Emanuela
A1 Castro, Elena
A1 Marin-Aguilera, Mercedes
A1 Lolli, Cristian
A1 Schepisi, Giuseppe
A1 Maugeri, Antonio
A1 Wingate, Anna
A1 Farolfi, Alberto
A1 Casadio, Valentina
A1 Medina, Ana
A1 Puente, Javier
A1 Vidal, Mª José Méndez
A1 Morales-Barrera, Rafael
A1 Villa-Guzmán, Jose C
A1 Hernando, Susana
A1 Rodriguez-Vida, Alejo
A1 González-Del-Alba, Aránzazu
A1 Mellado, Begoña
A1 Gonzalez-Billalabeitia, Enrique
A1 Olmos, David
A1 Attard, Gerhardt
A1 De Giorgi, Ugo
K1 Androgen receptor
K1 Androgen receptor–directed therapies
K1 Biomarker
K1 Castration-resistant prostate cancer
K1 Docetaxel
K1 Plasma DNA
AB Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR]=1.61, 95% confidence interval [CI]=1.08-2.39, p=0.018), but not PFS (HR=1.04, 95% CI 0.74-1.46, p=0.8) or PSA response (odds ratio=1.14, 95% CI=0.65-1.99, p=0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR=0.16, 95% CI=0.06-0.46, p
YR 2018
FD 2018-10-26
LK http://hdl.handle.net/10668/13576
UL http://hdl.handle.net/10668/13576
LA en
DS RISalud
RD Apr 6, 2025